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Introduction
After endorsement by the World Health Organization (WHO) in 2010, over 145 countries implemented the Xpert MTB/RIF assay by 2016 [1] . With such an increased capacity many countries are shifting from a smear microscopy (smear)-to an Xpert MTB/RIF -based tuberculosis (TB) diagnostic algorithm. In 2011, the Botswana Ministry of Health and Wellness adopted WHO guidelines and incorporated Xpert MTB/RIF into the national TB diagnostic algorithm [2] . Optimal performance of Xpert MTB/RIF relies on the quality of the sputum samples submitted for testing [3] . The WHO quality control standard underscores collection of quality sputum, and salivary samples were considered suboptimal and thus prone to rejection by testing laboratories [4] . The minimum required raw sputum sample for smear is 3 -5 ml [5] compared to 1ml for Xpert MTB/RIF per the Cepheid manufacturer (Cepheid, Sunnyvale, CA, USA) recommendation [6, 7] .
Yoon et al. and Bhat et
al.demonstrated that sputum gross appearance (quality) and volume (quantity) were associated with smear positivity [8, 9] . Similar to smear result, sputum quality and quantity may have an impact on the likelihood of obtaining a positive result when using Xpert MTB/RIF [3] .
While national TB programs are expanding implementation of Xpert MTB/RIF [1] , focus on collection of quality sputum with adequate volume has not been given priority [3] . Data on the effect of sputum quality and quantity on the yield of bacteriologically-confirmed TB using molecular tests such as Xpert MTB/RIF are scarce [3, 10] . We evaluated the proportion of bacteriologically-positive sputum samples with Mycobacterium tuberculosis (MTB) detected using Xpert MTB/RIF, compared to acid fast bacilli identified by smear, stratified by sputum quality and volume.
Methods

Study population
This is a sub-study of the Xpert MTB/RIF Package Rollout Evaluation Study using a stepped-wedge design (XPRES), registered at ClinicalTrials.gov, NCT02538952. Full details of the study protocol, including study populations, sample size, and procedures can be accessed in the published protocol [11] . XPRES enrolment began in 2012 as part of the Botswana's national Xpert MTB/RIF rollout, together with intensified TB case finding (ICF) activities and strengthening HIV patient retention interventions at 22 HIV treatment clinics prior to phased implementation of 13 GeneXpert instruments.
Tuberculosis screening
At enrolment and each follow-up visit (i.e., at two weeks, then monthly for the first three months and then quarterly for the remaining follow up period), adults and adolescents (combined into one adult group and defined as persons >12 years) and children (0-12 years old) were screened for TB symptoms. Per protocol, adults were screened for four TB symptoms (cough, fever, night-sweats and weight-loss) of any duration. Children were screened for weight-loss or failure to thrive (no weight gain over 3 months, enlarged lymph nodes (more than 1 x 1 cm), ≥ 2 weeks of cough, fever, fatigue/reduced playfulness, and profuse night-sweats [2, 12] .
Sputum collection, and assessment of macroscopic sputum quality
Patients who screened positive for any of these TB symptoms or signs were requested to provide four sputa; two were provided on the same day (Spot 1 and 2) and another two on the following day (Morning sputum collected at home and Spot 3 collected at the clinic). In the main study, XPRES, after GeneXpert instrument implementation each Spot 1 and 3 sputum specimen was tested by both Xpert MTB/RIF and smear at the peripheral laboratory. The focus of the sub-analysis was on patients who had at least one TB symptom and from whom at least one sputum was collected for both Xpert MTB/RIF and smear testing. Before GeneXpert instrument implementation each Spot 1 and 3 sputum specimen was tested only by smear at the peripheral laboratory as part of the main study. Spot 2 and morning sputum were submitted to the National TB Reference Laboratory for culture.
The culture result was needed for sensitivity analysis of the XPRES study and thus not included in this analysis. Initially and throughout the study, study nurses received training on how to collect a high quality sputum. Training included the importance of: (1) collecting a mucoid rather than salivary sample, (2) collecting the sample in a private but well-ventilated area outside the clinic, (3) use of a sputum collection job aid to guide patients through sputum production, and References in this manuscript to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation by the U.S. Government. (Table 2) .
Results
Association between sputum appearance and TB diagnosis
Of 954 tested sputum samples, 43.3% were classified as salivary. The (Table 3) .
Discussion
Our study demonstrated that among PLHIV with TB symptoms attending HIV care and treatment services, Xpert MTB/RIF was superior to smear at confirming the presence of MTB in sputum as previously reported [13] [14] [15] . Sputum gross appearance and quantity, however, were not predictive of bacteriologically-positive sputum by Xpert MTB/RIF or smear suggesting that despite a minimum required volume of sputum -especially for Xpert MTB/RIF testing -suboptimal quality of sputum might have affect the yield of bacteriologicallyconfirmed TB [16, 17] . These findings are consistent with a previous report by Ho et al. [18] who analysed over 20,000 sputum samples collected as part of an active case finding project in Vietnam; they reported that the macroscopic quality was similarly not predictive of bacteriologically-positive sputum. In the present study the only exception was sputum volume of 2ml to < 3ml that was predictive for a positive result when tested by Xpert MTB/RIF.
The percentage of samples classified as salivary in the present study was high at 43.3%, indicating potentially that, despite the training administered, a high proportion of patients were only able to produce salivary specimens. Recent studies from Kenya and Uganda also reported on the proportion of salivary sputa. In Kenya 44% of the samples were salivary and the study showed that salivary sputa had lower diagnostic yield than muco-purulent and mucoid sputa using Xpert MTB/RIF testing [10] . The study in Uganda examined presumptive TB patients screened with > 2 weeks of cough; the proportion of salivary sputa was at 16% [19] . In both the Kenya and the Uganda studies the proportion of salivary sample was not affected by HIV status. In Uganda, Xpert MTB/RIF test was conducted only among smear negative patients, and the diagnostic sensitivity, in contrast to our findings and those from Kenya, was significantly higher on salivary samples than mucoid sputa [19] . The Uganda findings on salivary sputum seems contrary to biological plausibility, showing higher diagnostic yield with lower quality sputa. However, the report from Uganda was consistent after comparison of diagnostic accuracy in reference to mycobacterial culture (higher culture positive among salivary than non-salivary). Given the higher positivity among salivary sputum samples was confirmed by culture, we are in agreement with Meyer et al that further study is essential exploring the possibility of potential dynamics affecting the Xpert MTB/RIF amplification in salivary sputum [19] . Ho et al. emphasized that assessment of sputum quality is a neglected aspect of accurate TB diagnostics [3] . Even though in the present study sputum quality was not predictive of diagnostic yield, we agree with Ho et al. that TB programs should continue to train providers on high quality sputum collection techniques. It is worth noting that despite the high cost of rolling out, Xpert MTB/RIF implementation in the world is expanding [1] . Such investments and their ultimate impact will potentially be compromised if TB diagnostic algorithms do not encompass collection of quality sputum [10] . A wide variability in the proportion of patients with salivary sample (24-70%) among clinics ( Figure 2 ) suggest an inconsistency in sputum collection practices across the clinics. Bhat et al have shown an association of improved sputum quality and diagnostic yield [9] . It is time that TB screening and diagnostic algorithms include standardized methods of sputum collection and introduce a sputum collection system less prone to variability as suggested by Ho et al. [3] .
In some previous reports, improving sputum quality increased TB diagnostic yield [18, [20] [21] [22] [23] [24] . Ho et al. were able to collect 99% mucoid or muco-purulent sputa by using sputum quality colour scale [18, 20] 
Mhalu et al. demonstrated that sputum submission instructional
videos increased the yield of TB cases through better quality of sputum samples [24] . In addition, training of health care workers and laboratorians on standardized methods of sputum collection and assessment of adequate good quality sputum can improve sputum quality [9] and measuring a volume in millilitres using a graded reference container can facilitate appropriate volume collection [9] .
With these various methods, achieving improved quality and quantity of sputum were possible but well-designed studies are still needed to define a more comprehensive approach and standard.
While endeavouring to standardize sputum collection methods, under current clinical and laboratory practices, at least five reasons stand out about why salivary sputum should not be rejected: (1) a high percentage of salivary sputum are still being collected in clinical practice by health workers [10] ; (2) sputum specimen appearance and volume are poor "negative predictors" of MTB in sputum [8, 18] ; (3) a limited volume (only 1ml) of non-concentrated sputum maybe acceptable for Xpert MTB/RIF testing [6, 7] ; (4) recent study demonstrate higher sensitivity of Xpert MTB/RIF in salivary samples than mucoid [19] and (5) above all, to minimize any missed opportunities for TB diagnosis [25] . Sputum rejection criteria, that consider salivary sample as unsuitable for testing should be reconsidered, particularly when using Xpert MTB/RIF testing [3] . In the present study, if salivary samples had been rejected, 12% and 6% of TB cases identified by Xpert MTB/RIF and smear, respectively, would have been missed as bacteriologically-confirmed TB case. Our study has limitations. Not all patients with TB symptoms were able to provide sputum, and for those who were able to provide sputum some did not receive sputum testing by both Xpert MTB/RIF and smear or
were not tested at all. However, the patient characteristics among those tested by both Xpert MTB/RIF and smear and not tested by both or at all were similar. We also did not assess nor document laboratorian skills in assessing the quality of sputa. Furthermore, there may have been inter and/or intra-operator variability in assessing sputum quality [26] .
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